# \[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\].

> PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-12037499-lanreotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-11-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-12037499-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-12037499-lanreotide-v1.json
- Content SHA-256: `58bb115edd186d161c21763be91a0e4863a23b1614189bc2efcc8ad40705c6ab`

## Claims and source pins

### Headline

\[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\]. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

### Summary

PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

### Paragraph 1

PubMed lists PMID 12037499 in Annales d'endocrinologie as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2002-04 (month precision). PeptideScanner associated the retained record with the identity slug lanreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`](#source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007))

## Sources

<a id="source-pubmed-observation-pmid-12037499-2016-11-24-270de4f82007"></a>
- **\[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\]. · retained source version 1:2016-11-24:current:270de4f82007e9e9aa2a6bfbc26aae2ad1b2b3cfef7893bb3030174c3c8232a0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/12037499/) (`pubmed-observation-pmid-12037499-2016-11-24-270de4f82007`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "\[Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-12037499-lanreotide-v1.json SHA-256: 58bb115edd186d161c21763be91a0e4863a23b1614189bc2efcc8ad40705c6ab.